E. David Crawford, MD, and Brian R. Hu, MD, presented “Nephron-Sparing Management of Low Grade UTUC with UGN-101 for Instillation-The OLYMPUS Trial.” for the Grand Rounds in Urology audience in August, 2019.
How to cite: Crawford, David E. and Hu, Brian R.. “Nephron-Sparing Management of Low Grade UTUC with UGN-101 for Instillation-The OLYMPUS Trial” August, 2019. Accessed Nov 2024. https://dev.grandroundsinurology.com/nephron-sparing-management-of-low-grade-utuc-with-ugn-101-for-instillation-the-olympus-trial/
Nephron-Sparing Management of Low Grade UTUC with UGN-101 for Instillation-The OLYMPUS Trial – Summary:
E. David Crawford, MD, and Brian R. Hu, MD, discuss the results of the use of UGN-101 to treat upper-tract urothelial cancer in the OLYMPUS trial, where it was shown to ablate low-grade tumors with a high initial complete response rate. They delve into the unique properties of UGN-101 and its successes and demonstrated side effects from the trial, as well as an upcoming study investigating a different formulation of the drug for treating bladder cancer.
ABOUT THE AUTHOR
Brian R. Hu, MD, is an Assistant Professor in Urologic Oncology at Loma Linda University. He received his MD from the University of California, Davis, School of Medicine. He also completed an internship and residency at UC Davis. He then completed his fellowship training at the University of Southern California. Dr. Hu treats the full spectrum of urologic cancers in both an open and minimally-invasive fashion. He has special research interest in clinical trials, testicular cancer, bladder cancer, and upper tract urothelial cancer. Dr. Hu is a Healing Hands Honoree.
